.png){kind=icon}
.png){kind=icon}
Return
Reassuring humoral and cellular immune responses to SARS-CoV-2 vaccination in participants with systemic sclerosis
.png){kind=icon}
OA
AI
DOI：10.1016/j.imlet.2024.106929.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Individuals with systemic sclerosis (SSc) are particularly susceptible to SARS-CoV-2 infections, yet it remains to be determined if they generate humoral and cellular responses comparable to controls following SARS-CoV-2 vaccinations. Herein, we collected blood and serum after second, third, and fourth SARS-CoV-2 vaccinations in patients with SSc and controls. Following each dose, participants with SSc mounted comparable serum antiRBD IgG, anti-RBD IgA, and spike-specific CD4(+) and CD8(+) T cell responses to those found in controls. At 3 months post dose 2, the frequencies of Th1, Th2, Th17, and Treg spike-specific CD4(+ ) T cells in participants with SSc did not differ from controls. At 2-6 weeks post dose 3, participants with SSc displayed reduced frequencies, but not numbers, of Th17-polarized spike-specific CD4(+ ) T cells. Thus, participants with SSc did not display significantly weaker humoral or cellular responses to SARS-CoV-2 vaccination than controls, enabling reassurance of vaccine immunogenicity in participants with SSc.
Keywords:
Systemic sclerosis
SARS-CoV-2
COVID-19
Vaccines
Autoimmune diseases
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
2.8
Papers:
4.5K
Citations:
6.1K